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Abstract
Background: Recent investigations suggest an increasing prevalence of Gram-positive and antibiotic-resistant bacteria
causing spontaneous bacterial peritonitis (SBP), probably related to changes in antibiotic prescription patterns, in particular
more widespread and long-term use of antibiotic prophylaxis with quinolones.
Objective: The primary objective of this study was to assess potential changes in the microbiology of SBP in two patient
cohorts studied at a 10-year interval. Further aims were to study prognostic factors and outcome of SBP.
Methods: A retrospective double-cohort study, including all ascitic cultures from patients with cirrhosis obtained 2003–2005
and 2013–2014, was conducted.
Results: In total 312 patients were included, 125 patients in the first and 187 patients in the second cohort. SBP was
diagnosed in 132 of 840 analyzed ascitic fluid samples; 62 samples were culture positive. An increase of Gram-positive
bacterial isolates was noted from 26% to 46% between cohorts (p¼ 0.122). The prevalence of multidrug-antibiotic–resistant
pathogens increased from 25% to 32% (p¼ 0.350). Survival after SBP among the two cohorts was comparable.
Conclusion: This single-center study in the Netherlands found a modest but nonsignificant increase in the proportion of
patients with SBP caused by Gram-positive bacteria and multidrug-antibiotic–resistant bacteria over a 10-year period. Our
findings differ from reported data in other countries and suggest empiric antibiotic prophylaxis and treatment of SBP should
be based on national and regional microbiological findings and resistance patterns.
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Key summary
. Spontaneous bacterial peritonitis (SBP) is a common complication in patients with liver cirrhosis with a
30-day mortality of 33%.
. A modest but non-signiﬁcant increase of Gram-positive bacteria and multidrug-antibiotic–resistant bac-
teria causing SBP was noted over a 10-year period in the Netherlands.
. There are substantial regional diﬀerences in bacterial ﬂora and antibiotic susceptibility causing SBP.
. Recommendations in antibiotic prophylaxis and treatment of SBP should carefully take microbiologic
geographical diﬀerences into account.
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Introduction
Spontaneous bacterial peritonitis (SBP) is a common
infection in patients with cirrhosis and ascites.
Reportedly, this infection can be diagnosed in up to
30% of cirrhotic patients with ascites who are admitted
to the hospital. SBP is associated with signiﬁcant mor-
bidity and mortality.1–4 Intestinal bacterial transloca-
tion, altered immunity and the presence of ascites are
key in the development of SBP.5–7
SBP is diagnosed by a polymorphonuclear neutrophil
(PMN) count in ascitic ﬂuid equal to or greater than 250/
ml. Approximately 40% of SBP episodes are culture posi-
tive.3,8,9 Numerous, in particular older, studies reported
that Gram-negative enteric bacteria were involved in the
majority of SBP episodes. International guidelines rec-
ommend third-generation cephalosporin as empirical
treatment for SBP and quinolones for secondary prophy-
laxis.10,11 However, in the last decade Gram-positive bac-
teria and antibiotic-resistant bacteria have been
increasingly found to cause SBP.3,8,9,12–14 This change
in microbiology has been attributed to long-term and
widespread quinolone use and increased prevalence of
hospital and intensive care unit admissions. These ﬁnd-
ings have raised doubts about the currently recommended
antibiotic strategy in SBP.
The prevalence of antibiotic-resistant pathogens sub-
stantially diﬀers geographically.15 Antibiotic consump-
tion has been identiﬁed as the main cause for increasing
rates of antibiotic resistance. The Netherlands is known
for a restrictive antibiotic policy and has had the lowest
antibiotic use in Europe for years.15–17 Consequently,
microbiological study results in SBP in our country
could diﬀer from those observed in other countries—
i.e. Spain, Greece, Germany and the United States—
over time. This would mean that international
guidelines for prophylaxis and treatment of SBP
would need to diﬀerentiate between countries based
on antibiotic resistance rates. Therefore, we investi-
gated causative microorganisms in two patient cohorts
who were hospitalized with a 10-year interval in a ter-
tiary referral hospital in the Netherlands. In addition,
we aimed to identify the patients most at risk for SBP
and to evaluate the associated short- and long-term
survival.
Materials and methods
All consecutive ascitic cultures performed in patients
with cirrhosis between January 2003 and December
2005 (ﬁrst cohort) and between January 2013 and
December 2014 (second cohort) at Erasmus MC,
University Medical Center, Rotterdam, were included.
Demographic, clinical, biochemical and survival
data from patient hospital records were retrospectively
studied to evaluate the prevalence, risk factors,
microbiology, and mortality of SBP. The study proto-
col conforms to the ethical guidelines of the 1975
Declaration of Helsinki as reﬂected in an approval
by the ethical review board of the Erasmus MC in
February 2017.
The diagnosis of cirrhosis was based on liver hist-
ology or a combination of clinical, biochemical, and
radiologic ﬁndings.18 SBP was deﬁned as a PMN
count equal to or greater than 250/ml in ascites without
evidence of an intra-abdominal source of infection.10,11
All ascites samples obtained during the two study per-
iods were studied, implying that, if applicable, multiple
samples per patient were taken into account. However,
only the ﬁrst positive culture per SBP episode, and thus
one culture per SBP episode, was included in the ana-
lysis. Multidrug-antibiotic–resistant organisms (MDR)
were deﬁned, according to international guidelines,
as an acquired resistance to at least three antibiotic
classes.19 Nosocomial acquisition was deﬁned as SBP
diagnosed at least 48 hours after hospital admission.
During the study periods, the standard antibiotic prophy-
laxis for SBP was norﬂoxacin 400mg daily.10,11,20 The
primary choice for empirical antibiotic treatment for
SBP was ceftriaxone 2000mg daily for ﬁve to seven
days and the secondary choice was amoxicillin/clavulanic
acid 1000/200mg every eight hours for ﬁve to seven days,
according to international guidelines.10,11,20
All ascitic ﬂuid samples were routinely analyzed
in the central clinical laboratory with automated deter-
mination of the white blood cell count with diﬀerential.
In addition, at least 10ml of ascitic ﬂuid was inoculated
at bedside under sterile conditions in aerobic and anaer-
obic blood culture bottles (Bactec) for culture
in the central medical microbiology laboratory. For
identiﬁcation of positive cultures, the ascitic ﬂuid was
plated on agar and current identiﬁcation methods were
used. Susceptibility was determined with the VITEK 2
system (VITEK AMS; bioMerieux Vitek Systems Inc,
Hazelwood, MO, USA). Cultures collected until 2013
were called resistant using Clinical and Laboratory
Standards Institute criteria; later cultures were called
resistant using European Committee on Antimicrobial
Susceptibility Testing criteria 2013.
Statistical analysis
A mean and standard deviation (SD) was computed
for approximately normally distributed variables and
compared using the Student’s t test. Non-normally dis-
tributed continuous variables were summarized by their
median and interquartile range (IQR), and compared
using the Mann-Whitney ranks sum test. Categorical
variables were expressed with percentages and com-
pared using the Chi-square test. A two-sided p value
<0.05 was considered signiﬁcant. Patients were
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followed up to a maximum of one year. This time frame
was chosen based on the severity of decompensated
advanced chronic liver disease. Survival was analyzed
using the Kaplan-Meier method. The actual 30-day
mortality and one-year mortality was calculated after
the ﬁrst ascitic ﬂuid analysis; both liver transplantation
and death were considered as events. The survival rates
were compared using log-rank test. Univariable and
multivariable Cox’s proportional hazard analyses
were carried out to identify independent predictors
for 30-day mortality and one-year mortality after
SBP. The variables selected for univariable analysis
were based on previous studies: gender, age, etiology
of liver disease, community- or nosocomial-acquired
SBP, positive microbial ascites culture, causative micro-
organism, antibiotic susceptibility, use of antibiotic
prophylaxis, use of immunosuppressant drug, hepato-
cellular carcinoma (HCC), model for end-stage liver
disease (MELD) score, albumin in serum, platelets in
serum, and protein in ascites at time of ascites analyses.
Variables with a p value of <0.10 in univariate analysis
were included in the multivariate Cox’s proportional
hazards model.
Results
In the ﬁrst (2003–2005) cohort of 125 patients, 343
ascitic ﬂuid samples were obtained for analysis. In the
second (2013–2014) cohort of 187 patients, 497 samples
were obtained. The diagnosis of SBP was established in
132 of the total 840 (16%) ascitic ﬂuid samples in
95 patients (Figure 1).
The total study population included 197 men and
115 women with a mean age of 56 years (12) and a
mean MELD score of 19 (8). Norﬂoxacin was used by
12% and 10% of patients at the time of paracentesis in
the ﬁrst and second cohort, respectively (p¼ 0.638).
The clinical characteristics of patients with and with-
out SBP are shown in Table 1. Patients with SBP had
more frequent liver disease of autoimmune origin, more
frequently used immunosuppressive drugs (p¼ 0.012)
and had higher baseline MELD scores (p¼ 0.020).
Microbiology
In the two cohorts a culture-positive SBP was found in
23/56 (41%) and 33/76 (43%) episodes with SBP,
respectively (Figure 1). The microbiological culture
1st cohort with 2nd cohort with
125 patients (2003 – 2005)
Spontaneous
bacterial
peritonitis
PMN-count
Culture
Mono-
bacterial
Multi-
bacterial
Multi-
bacterial
Culture
negative
Mono-
bacterial
negative
n = 33 (10%)
n = 23 (6%)
n = 0 (0%)
n = 43 (9%)
n = 27 (5%)
n = 6 (1%)
PMN-countSpontaneous
bacterial
peritonitis
n = 76 (15%)n = 287 (84%) n = 421 (85%)
< 250 cells/µL < 250 cells/µL
n = 56 (16%)
187 patients (2013 – 2014)
Analysis of ascites samples Analysis of ascites samples
n = 343 n = 497
Figure 1. Flowchart of study population.
PMN: polymorphonuclear neutrophil.
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results are shown in Table 2. In the ﬁrst cohort, 61% of
culture-positive SBP was due to Gram-negative bac-
teria vs. 51% in the second cohort. Candida albicans
was isolated in four cultures. Although the percentage
SBP with Gram-positive organisms increased over time,
the diﬀerences were not statistically signiﬁcant
(p¼ 0.122) (Table 2).
Antibiotic susceptibility patterns
In the ﬁrst cohort 5/20 (25%) of the isolated bacteria were
MDR versus 12/38 (32%) in the second cohort (Table 3).
There was no signiﬁcant change in prevalence of MDR
organisms over time (p¼ 0.350). In the MDR organisms,
the most frequently detected resistance mechanism was
due to extended-spectrum beta-lactamase (ESBL) produc-
tion (Escherichia coli n¼ 9, Klebsiella n¼ 1). Furthermore,
methicillin-resistant Staphylococcus aureus (MRSA)
(n¼ 4), intrinsically cephalosporin-resistant Enterobacter
(n¼ 2), and vancomycin-resistant Enterococci (VRE)
(n¼ 1) were found. There was no evidence that the risk
of SBP caused by MDR organisms was related to a
Gram-negative or Gram-positive microbiologic isolate
(p¼ 0.192), a nosocomial acquisition of the infection
(p¼ 0.677), a previous history of SBP (p¼ 0.245), or the
use of antibiotic prophylaxis (p¼ 0.316).
Table 1. Clinical characteristics of the study population with and
without SBP.
SBP
negative
(n¼ 217)
SBP
positive
(n¼ 95)
p
value
Male (%) 138 (64%) 59 (62%) 0.802
Age in years 57 (12) 54 (13) 0.036
Etiology of cirrhosis (%)
Alcohol 92 (42%) 31 (33%) 0.045
Viral 51 (24%) 23 (24%)
Autoimmune 28 (13%) 24 (25%)
Other 46 (21%) 17 (18%)
Child-Pugh class (%)
A 25 (12%) 5 (5%) 0.215
B 74 (34%) 33 (35%)
C 118 (54%) 57 (60%)
MELD score 19 (8) 21 (8) 0.020
Creatinine (mmol/l) 96.8 (1.7) 110.1 (1.8) 0.052
Albumin (g/l) 29 (6) 29 (6) 0.912
INR 1.5 (1.0) 2.0 (1.5) 0.006
Bilirubin (mmol/l) 62 (3) 76 (4) 0.260
Thrombocytes (109/l) 107 (2) 97 (2) 0.304
Ascites protein (g/l) 10.6 (2.0) 16.3 (2.6) 0.009
Hepatocellular carcinoma 30 (14%) 11 (12%) 0.589
Diabetes mellitus 37 (17%) 11 (12%) 0.218
Use of immunosuppressant
drug
21 (10%) 19 (20%) 0.012
Use of norfloxacin 26 (12%) 8 (8%) 0.353
SBP: spontaneous bacterial peritonitis; MELD: model for end-stage liver
disease; INR: international normalized ratio. Significant p values (<0.050)
are highlighted in boldface.
Table 2. Microbiological findings in two cohorts of patients; 62
organisms were identified in 56 episodes of culture-positive
spontaneous bacterial peritonitis.
Cohort
2003–2005
(n¼ 23)
Cohort
2013–2014
(n¼ 39)a
Gram-negative bacteria 14 (61%) 20 (51%)
Escherichia coli 9 13
Enterobacter aerogenes – 2
Enterobacter cloacae – 2
Pseudomonas aeruginosa 2 –
Klebsiella pneumoniae 1 3
Morganella morganii 1 –
Aeromonas spp. 1 –
Gram-positive bacteria 6 (26%) 18 (46%)
Staphylococcus aureus 1 3
Staphylococcus haemolyticus – 1
Staphylococcus (coagulase negative) 3 3
Enterococcus faecium – 5
Streptococcus oralis 1 3
Streptococcus anginosus – 1
Streptococcus salivarius – 1
Streptococcus viridans – 1
Streptococcus pneumoniae 1 –
Yeast 3 (13%) 1 (3%)
Candida albicans 3 (13%) 1 (3%)
aIncluding six cultures showing two microorganisms.
Table 3. Antimicrobial susceptibility patterns of bacteria from
culture-positive spontaneous bacterial peritonitis (SBP).
Bacterial isolates in SBP
(n¼ 58)
Cohort
2003–2005
(n¼ 20)
Cohort
2013–2014
(n¼ 38)
p
value
Multidrug resistant 5 (25%) 12 (32%) 0.350
Norfloxacin resistanta 3 (15%) 9 (24%) 0.274
Ceftriaxon resistanta 3 (15%) 5 (13%) 0.952
Amoxicillin/clavulanic
acid resistanta
8 (40%) 8 (21%) 0.254
aIntrinsically and/or acquired antimicrobial resistance.
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Three of the 20 (15%) and six of the 38 (16%) iso-
lated organisms were norﬂoxacin resistant, in the ﬁrst
and second cohort, respectively (p¼ 0.274).
Analysis with respect to ceftriaxone showed that in
the ﬁrst cohort 3/20 (15%) of bacterial isolates were
resistant to this agent as compared to 5/38 (13%) in
the second cohort. Amoxicillin/clavulanic acid-resistance
was slightly more prevalent. In the ﬁrst cohort 6/20
(30%) organisms were found to be resistant versus
8/38 (21%) in the second cohort. The frequency of cef-
triaxone and amoxicillin/clavulanic acid-resistant organ-
isms did not diﬀer signiﬁcantly between the cohorts
(p¼ 0.952 and p¼ 0.254, respectively) (Table 3).
Survival
At one year, 153 patients had died (49%) and 48
patients had received a liver transplant (15%).
Furthermore, 83 patients (27%) were alive after one
year, while 28 patients (9%) were lost to follow-up.
The median follow-up time of the patients not reaching
the endpoint of death or liver transplantation was 365
days (IQR 12 days). The survival of patients with
SBP did not diﬀer signiﬁcantly between the cohorts
(log-rank p¼ 0.442), nor did survival diﬀer signiﬁcantly
between the cohorts for patients without SBP (log-rank
p¼ 0.216).
The median survival after the ﬁrst ascites analyses
was 168 days for SBP-negative patients and 77 days for
SBP-positive patients (log-rank p¼ 0.001) (Figure 2).
The 30-day mortality rate was 33% (32/95) for patients
with SBP compared to 25% (55/217) for patients
without SBP (Figure 2). Univariable and multivariable
Cox-regression analyses were carried out to identify
risk factors for 30-day mortality and one-year mortality
after SBP. MELD score was the only independent
predictive factor for 30-day mortality (hazard ratio
(HR) 1.106 per point, 95% CI 1.061–1.154, p< 0.001)
and one-year mortality (HR 1.060 per point, 95% CI
1.030–1.091, p< 0.001) (Table 4).
Discussion
In this single-center study in the Netherlands, the
microbiological characteristics and antibiotic suscepti-
bility patterns of organisms causing SBP in liver
cirrhosis patients were compared between the periods
2003–2005 and 2013–2014. No signiﬁcant increase
in Gram-positive bacteria was observed and Gram-
negative bacteria remained the primary cause.
Bacteria resistant to empirical treatment with third-
generation cephalosporin accounted for 13%–15% of
all causative pathogens.
There was no evidence that mortality was inﬂuenced
by causative microorganisms, antibiotic susceptibility,
use of prophylactic antibiotics, intensive care admission
or a nosocomial acquisition of SBP. The main
predictors for mortality were age, MELD score, and
platelet count.
Our most important ﬁnding is that in the era of
quinolone prophylaxis for SBP, we cannot conﬁrm
observations made elsewhere regarding a signiﬁcant
increase in Gram-positive and MDR organisms causing
SBP.3,8,9,12,13 Although in the Netherlands antibiotics
are used prudently, a rise in quinolone use in the last
decades has been described.21,22
Third-generation cephalosporin may poorly cover
the causative pathogens in SBP, with reported anti-
biotic resistance rates ranging from 57% to
69%.9,23,24 However, our results show a susceptibility
rate of 85–87%. We hypothesize this diﬀerence can be
most likely attributed to diﬀerent national antibiotic
policies. High consumption of antibiotics has been
related to higher rates of antibiotic resistance.15 The
Netherlands has always had a restrictive national
policy regarding antibiotic prescription and a conserva-
tive approach toward the prescription of new broad-
spectrum antibiotic agents.15,16,25
The microbiology and susceptibility patterns’ diﬀer-
ences can be hospital and region dependent, implying
diﬃculties with recommending antibiotic treatment and
prophylaxis in international guidelines. The results of
this study in the Netherlands do not support the need to
revise guidelines as previously proposed.3,23 Empirical
antibiotic treatment should be based on known regio-
nal and national diﬀerences of antibiotic resistance
patterns.
A previous study from our institution on the micro-
biology of SBP in the period 1987–1991, before the
implementation of long-term quinolone prophylaxis in
the relevant patient population, reported that causative
Patients without SBP
Patients with SBP
100
Al
iv
e 
(%
)
80
60
40
20
0
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Days
240 300 360
Figure 2. One-year mortality after first ascites analysis.
Spontaneous bacterial peritonitis (SBP)-negative patients (solid
line) have a median survival of 168 days and SBP-positive patients
(dotted line) of 77 days (log-rank p¼ 0.001).
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pathogens were isolated in 25 of 31 SBP episodes.26
Gram-negative bacteria were detected in 60% of the
episodes and Gram-positive bacteria in 40% of the
episodes. Despite the small sample size, the proportions
of causative pathogens seem comparable to those iden-
tiﬁed in the cohorts reported here.
Although optimizations in bacterial culture tech-
niques have been implemented, an organism was iso-
lated in a minority of all SBP episodes (40%). This is a
stable percentage over the last decade and similar pro-
portions have been documented in other studies.3,8,9
It may be expected that, with technologies arising
from bacterial DNA detection and microbiome studies,
more causative pathogens can be identiﬁed rapidly in
the future for targeted antibiotic therapy.
There are a few limitations of the study regarding
methodology. This study was designed as a retrospect-
ive, double-cohort study, which implied some labora-
tory and clinical data were missing. For instance, we
have no information about short-term antibiotic use
prescribed by general practitioners and clinicians out-
side the hospital, but it is not to be expected that this
would diﬀer signiﬁcantly between the cohorts.
Furthermore, multiple tests have been performed that
may lead to an increased risk of ﬁnding spurious sig-
niﬁcant results and results should be interpreted while
keeping this in mind. Prospective cohort studies com-
paring multiple regions during a large time frame could
provide more insight as to the microbiology of SBP in
diverse regions over time.
In this study we show that the microbiology of
pathogens causing SBP did not change signiﬁcantly in
our center over the last decade. These ﬁndings suggest
that guidelines with respect to antibiotic prophylaxis
and treatment of SBP should carefully take into
account potential national and regional diﬀerences in
the microorganisms causing SBP and antibiotic resist-
ance patterns.
Table 4. Demographic and clinical factors after SBP in 95 patients predicting one-year mortality using Cox-regression analysis.
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Gender <0.001
Female (ref.) 1
Male 0.424 0.263–0.682
Age (per year) 0.999 0.981–1.017 0.911
Etiology 0.206
Alcohol (ref.) 1
Viral 0.841 0.444–1.596
Autoimmune 1.545 0.836–2.858
Other 0.837 0.431–1.625
Acquisition SBP 0.078
Community (ref.) 1
Nosocomial 1.761 0.938–3.303
Positive microbial ascites culture 1.406 0.886–2.231 0.148
Causative microorganism type 0.561
Gram-negative bacteria (ref.) 1
Gram-positive bacteria 0.764 0.359–1.625
Yeast 1.511 0.444–5.146
Multidrug-resistant microorganism 1.989 0.972–4.073 0.060
Antibiotic prophylaxis 0.662 0.286–1.531 0.335
Immunosuppressant use 0.508 0.260–0.992 0.047
HCC 0.971 0.465–2.026 0.937
MELD score (per point) 1.060 1.030–1.091 <0.001 1.060 1.030–1.091 <0.001
Albumin in serum (per point) 0.967 0.927–1.008 0.109
Platelets in serum (<150109/l) 2.179 1.226–3.870 0.008
Low protein in ascites (<15 g/l) 1.287 0.530–3.124 0.578
SBP: spontaneous bacterial peritonitis; MELD: model for end-stage liver disease; HCC: hepatocellular carcinoma; HR: hazard ratio; CI: confidence interval.
Significant p values in univariable analysis (<0.100) and in multivariable analysis (<0.050) are highlighted in boldface.
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